NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Safety of Oral Resin for Treatment of Hyperkalemia in Chinese Patients With Renal Insufficiency

CompletedN/A

Sponsor: AstraZeneca

Conditions: Hyperkalaemia

Countries: China

It is a multicenter, prospective, non-interventional cohort study, in order to evaluate the safety of oral resin for treatment of hyperkalemia in Chinese patients with renal insufficiency.

Eligibility overview

Sex: ALL

Age: 18 Years to 130 Years

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* Age ≥ 18 year-old
* Provision of patient informed consent prior to any study procedure
* Patients diagnosed as CKD or AKI
* HK (sK+ \> 5.0 mmol/L) diagnosed by physicians within 1 year before Day 1
* Currently taking CPS/SPS, or have been prescribed and agree to start taking CPS/SPS since Day 1.

Exclusion Criteria:

* Being unable to comply with study-specified procedures
* Has ever participated in current study before, or participating in any interventional study at Day 1 or within the last 3 months before Day 1.

Locations (16)

Beijing, Beijing Municipality, China
Beijing, China
Dalian, China
Dongyang, China
Hangzhou, China
Hefei, China
Jinan, China
Kaifeng, China
Ningbo, China
Qingdao, China
Shijiazhuang, China
Tianjin, China
Xuzhou, China
Yangzhou, China
Zhangjiagang, China
Zhengzhou, China